BioTrove, Inc. Launches Next-Generation Mass Spectrometry System, Enables Accelerated Drug Discovery Research

WOBURN, Mass.--(BUSINESS WIRE)--BioTrove, Inc. today announced launch of its second-generation RapidFire Mass Spectrometry system. Capable of fully-automated, unattended operation for up to eight hours, during which a total of ten 384-well microtiter plates can be analyzed, the enhanced system was developed in collaboration with a major U.S. pharmaceutical company that confidentially funded the project in order to receive accelerated delivery of the first instrument.
MORE ON THIS TOPIC